James Fagin

James Fagin is a pre-eminent authority on the molecular biology of thyroid cancer and the development of targeted therapies for RET and BRAF-driven thyroid malignancies. His foundational research characterized the oncogenic signaling of BRAF V600E in papillary thyroid cancer and RET/PTC rearrangements arising after radiation exposure. He has contributed to the clinical development of selpercatinib, pralsetinib, and other RET inhibitors for RET-mutated and RET fusion-positive thyroid cancers. His translational research program has advanced mechanistic understanding of how MAPK pathway activation drives thyroid cancer dedifferentiation and radioiodine resistance.